Reneo Pharmaceuticals (RPHM) Financials
$1.81
As on 04-Oct-2024 18:32EDT
Market cap
$61 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
1.47
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cost of Revenue
|
0.12
|
0.53
|
0.53
|
0.05
|
0.04
|
0.03
|
|||||
|
Gross Profit
|
0.62
|
-0.53
|
-0.53
|
-0.05
|
-0.04
|
-0.03
|
|||||
|
Operating Expenses
|
62.81
|
83.05
|
53.85
|
39.82
|
19.55
|
15.47
|
|||||
|
Operating Profit (EBIT)
|
-62.88
|
-83.05
|
-53.85
|
-39.82
|
-19.55
|
-15.47
|
|||||
|
Other Income
|
--
|
--
|
1.89
|
--
|
--
|
--
|
|||||
|
Profit before Tax
|
-56.54
|
-77.39
|
-51.96
|
-39.77
|
-19.47
|
-12.44
|
|||||
|
Provision for Tax
|
0.99
|
0.65
|
-1.89
|
-0.19
|
-0.17
|
-3.04
|
|||||
|
Profit after Tax (Net Income)
|
-56.54
|
-77.39
|
-50.06
|
-39.77
|
-19.47
|
-12.44
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
-51.96
|
-39.77
|
-19.47
|
-12.44
|
Liabilities ($ Mln) |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
76.87
|
88.61
|
99.97
|
147.21
|
-42.12
|
-23.13
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
0.50
|
0.65
|
1.09
|
0.61
|
92.76
|
45.69
|
|||||
|
Current Liabilities
|
1.35
|
18.18
|
7.12
|
6.20
|
4.58
|
2.94
|
|||||
|
Total Liabilities
|
80.07
|
107.44
|
108.18
|
154.02
|
55.22
|
25.51
|
Assets ($ Mln) |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
0.73
|
0.81
|
1.83
|
0.29
|
0.20
|
0.10
|
|||||
|
Current Assets
|
77.99
|
106.62
|
106.35
|
153.73
|
55.03
|
25.41
|
|||||
|
Total Assets
|
80.07
|
107.44
|
108.18
|
154.02
|
55.22
|
25.51
|
|||||
|
Total Debt*
|
0.82
|
0.97
|
1.46
|
--
|
92.72
|
45.65
|
|||||
|
Net Current Assets
|
76.64
|
88.45
|
99.23
|
147.53
|
50.45
|
22.47
|
Cashflow ($ Mln) |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-63.68
|
-47.36
|
-37.98
|
-18.54
|
-12.51
|
|||||
|
Cash Flow from Investing Activities
|
--
|
--
|
-57.84
|
-23.38
|
7.38
|
-7.24
|
|||||
|
Cash from Financing Activities
|
--
|
60.87
|
0.47
|
132.41
|
47.27
|
24.99
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
-104.73
|
--
|
--
|
--
|
Financials Ratios |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash EPS ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Adjusted Book Value ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
Profitability Ratios |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-81.03
|
-40.27
|
-40.21
|
-53.23
|
--
|
|||||
|
ROE (%)
|
-68.33
|
-82.07
|
-40.51
|
-75.68
|
59.67
|
--
|
|||||
|
ROA (%)
|
-46.76
|
-71.78
|
-38.19
|
-38.01
|
-48.22
|
--
|
|||||
|
EBIT Margin (%)
|
-4,286.57
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Net Margin (%)
|
-3,851.29
|
--
|
-2,644.59
|
--
|
--
|
--
|
|||||
|
Cash Profit Margin (%)
|
-0.03
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EBIT Growth (%)
|
4.18
|
-51.79
|
-36.34
|
-103.65
|
-26.36
|
--
|
|||||
|
Net Profit Growth (%)
|
3.25
|
-54.58
|
-25.88
|
-104.32
|
-56.52
|
--
|
|||||
|
EPS Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Book Value Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Price / Book Value
|
0.79
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
0.16
|
1.24
|
1.85
|
3.71
|
--
|
--
|
|||||
|
Close Price ($)
|
15.10
|
16.00
|
23.30
|
85.50
|
--
|
--
|
|||||
|
High Price ($)
|
92.10
|
112.95
|
95.98
|
171.80
|
--
|
--
|
|||||
|
Low Price ($)
|
9.80
|
9.80
|
17.90
|
59.50
|
--
|
--
|
|||||
|
Market Cap ($ Cr)
|
60.84
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.01
|
0.01
|
--
|
-2.20
|
-1.97
|
|||||
|
Short term debt to equity ratio
|
0.00
|
0.00
|
0.00
|
--
|
--
|
--
|
|||||
|
Current Ratio
|
57.86
|
5.87
|
14.93
|
24.79
|
12.01
|
8.64
|
|||||
|
Quick Ratio
|
57.86
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Interest Coverage
|
-26.82
|
--
|
-28.68
|
-829.54
|
--
|
--
|
Operating Efficiency Ratios |
TTM | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Asset Turnover
|
0.01
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Receivable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Inventory Days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Payable days
|
--
|
3,690.76
|
1,351.56
|
10,701.83
|
7,156.93
|
5,822.51
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
--
|
--
|
--
|
--
|